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ABSTRACT
This guideline was provided by the Japanese Association for Complement Research targeting clinicians for
making an accurate diagnosis of hereditary angioedema (HAE), and for prompt treatment of the HAE patient in
Japan. This is a 2010 year version and will be updated according to any pertinent medical advancements.
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PURPOSE OF THIS GUIDELINE
This guideline was provided by the Japanese Associa-
tion for Complement Research targeting clinicians for
making an accurate diagnosis of hereditary angioe-
dema (HAE), and for prompt treatment of the HAE
patient.
HAE is caused by a deficiency or improper function
of the inhibitor of complement component protein C1
(C1-INH), which affects the blood vessels. Patients
with HAE can develop rapid swelling of the hands,
feet, limbs, face, intestinal tract, larynx or trachea.
HAE is relatively easy to diagnose if you are familiar
with the disease and it may be treated efficiently. The
lack of an accurate diagnosis can have serious conse-
quences. Patients with misdiagnosed HAE may un-
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Face and Cervical Region
Subcutaneous Edema-
Face and Cervical Region Abdominal Symptoms
Follow-up - + + +
Tranexamic acid - + + +
C1-INH + +/- + +
Intubation in ICU + - - -
dergo unnecessary medical procedures (e.g. appen-
dectomy, exploratory laparotomy). We all hope that
patients suffering from the disease will be immedi-
ately diagnosed with HAE and treated appropriately.
We will update this guideline according to any perti-
nent medical advancements.
GENERAL INFORMATION ON HAE
a) Epidemiology: one in every 10,000 to 150,000 peo-
ple (mostly reported as one in every 50,000).
b) Types of HAE
i) Type 1, autosomal dominant inheritance (85%
of all HAE): Low amount of C1-INH protein
and low level of C1-INH activity.
ii) Type 2, autosomal dominant inheritance (15%
of all HAE): Normal or increased amount of
C1-INH protein and low level of C1-INH activ-
ity.
iii) Type 3 is very rare and not reported in Japan,
occurring mostly in females (estrogen-
dependent). Details of the pathogenesis are
unknown, and the mutation of coagulation fac-
tor XII is detected in some families. Both C1-
INH protein and C1-INH activity are normal.
iv) Sporadic cases not related to family history are
observed in approximately 25% of all HAE.
DIAGNOSIS
HAE is often unrecognized or misdiagnosed because
it is rare, and its symptoms are similar to many other
more common angioedema.
a) Differential diagnosis for HAE: acquired angioe-
dema (AAE), drug-induced angioedema, etc.
b) Symptoms of suspected HAE
i) Angioedema can be caused in any tissues and
its symptoms may vary in each organ.
•Laryngeal edema - the fatality rate is 30%
when not appropriately treated. Rare in chil-
dren under 3 years old.
•Subcutaneous edema, submucosal edema
(not associated with itching, can be seen all
over the body, swelling is sometimes below
the surface of the skin).
•Digestive symptoms (abdominal pain, nau-
sea, vomiting, diarrhea).
ii) Angioedema attacks may be induced by psy-
chological stress, physical stress such as
trauma, tooth extraction, surgical operation,
overwork, pregnancy, menstruation, drugs,
etc.
iii) Angioedema usually peak within 24 hours and
subside within 72 hours, however, they may
continue for more than 72 hours in some
cases.
iv) Approximately 75% of HAE patients have fam-
ily histories.
v) Attacks can occur in all ages.
c) Laboratory serum test
C1-INH activity is low in all HAE patients. There-
fore, C1-INH activity is the most important meas-
urement for the diagnosis of HAE and this test is
covered by health insurance in Japan. During an
angioedema episode, the level of complement
component C4 decreases in 98% of HAE patients,
and therefore may be a good marker for the diag-
nosis of HAE during its episode.
d) Determination of HAE types
To determine the type of HAE, quantification of
C1-INH protein is required, although the cost is
not covered by Japanese health insurance.
•Low C1-INH protein - Type 1 HAE
•Normal C1-INH protein - Type 2 HAE
e) When there is no family history, diagnosis should
be differentiated from AAE. When the level of
C1q (not covered by the Japanese health insur-
ance) is low, it can generally be diagnosed as
AAE. However, in rare cases, low levels of C1q
can be detected in HAE and genetic analysis is re-
quired for accurate diagnosis.
f) When Type 3 HAE is suspected, a mutation of
Factor XII may be identified.
TREATMENT DURING AN EPISODE (Table
1)
a) Laryngeal edema
i) C1-INH replacement therapy (for less than 50
kg, 500 units and for more than 50 kg, 1,000 to
1,500 units, intravenous injection).
ii) Intra-tracheal intubation or tracheotomy in In-
tensive Care Unit for respiratory distress by
airway stenosis.
b) Subcutaneous edema (excluding face and cervical
region)
i) Follow-up first.
ii) If no improvement is seen, give the following
treatment: Tranexamic acid 15 mgkg every 4
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hours. For severe cases in which symptoms
do not improve by tranexamic acid treatment
alone, C1-INH replacement therapy is re-
quired (for less than 50 kg, 500 units and for
more than 50 kg, 1,000 to 1,500 units, intrave-
nous injection).
c) Subcutaneous edema (face and cervical region)
i) Tranexamic acid (15 mgkg every 4 hours).
ii) C1-INH replacement therapy (for less than 50
kg, 500 units and for more than 50 kg, 1,000 to
1,500 units, intravenous injection).
d) Abdominal symptoms
i) Tranexamic acid (15 mgkg every 4 hours).
ii) C1-INH replacement therapy (for less than 50
kg, 500 units and for more than 50 kg, 1,000 to
1,500 units, intravenous injection).
SHORT-TERM PROPHYLAXIS
a) Cases with minimal stress: dental treatment (less
invasive), etc. Treatment for prevention is not re-
quired, but C1-INH replacement should be ready
for use.
b) Cases with intensive stress: highly invasive dental
treatment, surgical operations, etc. Give C1-INH
replacement therapy (for less than 50 kg, 500
units, and for more than 50 kg, 1,000 to 1,500
units, intravenous injection) an hour prior to the
operation. Furthermore, a second C1-INH re-
placement therapy should be prepared.
LONG-TERM PROPHYLAXIS
The following treatment is recommended for patients
with a history of laryngeal edema, those who develop
symptoms once or more a month, andor suffered
from symptoms for more than 5 days a month.
a) Tranexamic acid
i) 30-50 mgkgday administered in divided
doses 2-3 times a day.
ii) Adverse reactions: muscle ache, muscle weak-
ness, fatigue, and reduction in blood pressure.
b) Danazol
i) 2.5 mgkgday(maximum 200 mgday) will
be administered for one month, if it is not ef-
fective, 300 mgday will be administered for
one month, and if it is still not effective, 400
mgday will be administered for one month. If
200 mgday is effective, 100 mgday will sub-
sequently be administered for one month and
the amount will be reduced to 50 mgday or
100 mgevery second day.
ii) Contraindication: children, pregnant women,
lactating women, and cancer patients.
iii) Adverse reactions: virilization, hepatic disor-
der, hypertension, lipid abnormality, poly-
cythemia, and hemorrhagic cystitis.
iv) Follow-up: Blood testing is required every 6
months. For patients treated with more than
200 mgday Danazol, an abdominal ultra-
sonography is required every 6 months and
for cases treated with less than 200 mgday an
abdominal ultrasonography is required every
year, due to a possibility of hepatic tumori-
genesis.
REFERENCE MATTERS FOR DIAGNOSIS
a) For the initial screening for HAE, a serum C4
measurement during attacks should be consid-
ered.
i) Low C4 level → Conduct C1-INH activity
measurement.
ii) Normal C4 level→ HAE can basically be ruled
out.
b) Measurement of the C1-INH activity is essential
for making an accurate diagnosis of HAE
i) Low C1-INH level→ It can be diagnosed with
angioedema caused by a deficiency of C1-INH.
Differentiate the types as follows.
•With a family history→ It can be diagnosed
as HAE.→ Conduct quantitation of C1-INH.
→ If the level is low, it can be diagnosed as
Type 1, and if the level is normal or in-
creased, it can be diagnosed as Type 2.
•No family history → Conduct serum C1q
measurement and if the level is low, it can
be diagnosed as AAE. However, it should be
taken into account that low C1q can occur in
some HAE patients. → A genetic analysis is
desired in order to make an accurate diag-
nosis.
ii) Normal C1-INH level → Suspect of Type 3 or
drug-induced angioedema.→ Confirm hisher
medication history ( especially, anti-
hypertensive drugs, estrogen preparations). In
addition, Type 3 has not been reported in Japa-
nese; however, according to reports in Cauca-
sians, it is related to family history and occurs
mostly in women.
NOTES
Please contact us if you have any opinions about this
guideline. Contact: Takahiko Horiuchi, Steering
Committee, The Japanese Association for Comple-
ment Research. E-mail: horiuchi@intmed1.med.
kyushu-u.ac.jp.
Please refer to our website at http:square.umin.a
c.jpcomplif you have any concerns about C1-INH
activity measurement, protein quantitation, and ge-
netic analysis.
C1-INH formulation is provided as Berinert P
(trade name)(CSL Behring) in Japan. Information on
hereditary angioedema can be obtained from homep-
age of CSL Behring at http:www.cslbehring.co.jp,
or a dedicated website for hereditary angioedema
“HAE Information Center” at http:www.hae-info.jp.
For example, you can find information like “Tranex-
amic acid is provided as Transamin (trade name)
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(Daiichi Sankyo), etc.”, and “Danazol is provided as
Bonzol (trade name)(Mitsubishi Tanabe Pharma),
etc.”.
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